Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
Li J, Wang M, Zhang B, Wu X, Lin TL, Liu XF, Zhou Y, Zhang XH, Xu H, Shen LJ, Zou J, Lu P, Zhang D, Gu WJ, Zhang MX, Pan J, Cao H; Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association. Li J, et al. Among authors: zhang b, zhang mx, zhang d, zhang xh. World J Gastroenterol. 2018 Dec 14;24(46):5189-5202. doi: 10.3748/wjg.v24.i46.5189. World J Gastroenterol. 2018. PMID: 30581268 Free PMC article.
Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.
Li J, Zhang X, Deng Y, Wu X, Zheng Z, Zhou Y, Cai S, Zhang Y, Zhang J, Tao K, Cui Y, Cao H, Shen K, Yu J, Zhou Y, Ren W, Qu C, Zhao W, Hu J, Wang W, Yang J, Shen L. Li J, et al. Among authors: zhang j, zhang x, zhang y. Oncologist. 2023 Feb 8;28(2):187-e114. doi: 10.1093/oncolo/oyac242. Oncologist. 2023. PMID: 36477870 Free PMC article. Clinical Trial.
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
Li J, Zhang J, Zhang Y, Qiu H, Zhou Y, Zhou Y, Zhang X, Zhou Y, Zhu Y, Li Y, Wang M, Shen K, Tao K, Wu X, Wang H, Zhang B, Ling J, Ye Y, Wu X, Qu H, Ma Y, Jiao X, Zheng H, Jin J, Liu Z, Tan M, Fang Y, Zhang P, Zhang N, Lei C, Cai Z, Liang B, Peng Z, Huang Z, Dong J, Shen L. Li J, et al. Among authors: zhang n, zhang b, zhang p, zhang j, zhang x, zhang y. Eur J Cancer. 2024 Jan;196:113439. doi: 10.1016/j.ejca.2023.113439. Epub 2023 Nov 14. Eur J Cancer. 2024. PMID: 37980854 Clinical Trial.
168,444 results
You have reached the last available page of results. Please see the User Guide for more information.